CCBIO seminar: Therese Sørlie
FGFR1 in hormone receptor positive breast cancer
Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo
Luminal breast cancer (expressing estrogen receptor and/or progesterone receptor) accounts for approximately 75% of all breast cancers tumors and are associated with relatively good survival due to efficient treatment with endocrine therapy. Despite this, a significant proportion (up to 40 %) will in the longer term, develop resistance to therapy and disease recurrence. Many different growth factor receptors and signaling pathways are involved in breast cancer development and progression and in development of resistance. One such growth factor receptor, Fibroblast growth factor receptor 1 (FGFR1), is amplified in up to 27% of luminal cancers (highest in luminal B subtype) and is an independent prognostic marker associated with short overall survival rates. In this seminar, I will discuss our ongoing project on FGFR1 and its potential as a biomarker and target for therapy in luminal breast cancer. Through in vitro and in vivo experiments, we have shown that targeting FGFR1 inhibits cell proliferation and slows down tumor growth, and may also re-sensitize resistant cells to hormone treatment.
Chairperson: Lars Akslen, CCBIO